Kymera Therapeutics (KYMR) Tops Q1 EPS by 2c

Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.69), $0.02 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $10.3 million versus the consensus estimate of $13.78 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen